Cytrx Corp. (CYTR) Stock News

USA - NASDAQ:CYTR -

0.31

-0.07 (-18.38%)

Last: 6/3/2019, 8:21:27 PM

0.31

0 (0%)

After Hours: 6/3/2019, 8:21:27 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

CYTR Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: LadRx Corporation - Mentions: LADX

LadRx Corporation Announces OTCQB Ticker Change to LADX

3 years ago - By: CytRx Corporation

CytRx Corporation Relaunches as LadRx Corporation

3 years ago - By: CytRx Corporation

European Patent Office Awards CytRx Key Patent

3 years ago - By: CytRx Corporation

CytRx Welcomes Cary J. Claiborne to the CytRx Board of Directors

3 years ago - By: CYTRX CORPORATION

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

4 years ago - By: CytRx Corporation

CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

4 years ago - By: CytRx Corporation

CytRx Partners with Oncology Development Expert to Advance LADR Platform

4 years ago - By: CytRx Corporation

CytRx Issues Open Letter to Stockholders Regarding Recent Corporate Progress

4 years ago - By: Benzinga - Mentions: ORPH

Orphazyme Calls For Court-Mediated Restructuring, Lays Off 50% Workforce

4 years ago - By: CytRx Corporation

CytRx Comments on Orphazyme's Update on European Union Regulatory Review of Arimoclomol in Niemann-Pick Disease Type C

4 years ago - By: CytRx Corporation

CytRx Highlights Orphazyme's Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

4 years ago - By: CytRx Corporation

CytRx to Hold Town Hall for Stockholders on Thursday, January 20th

4 years ago - By: CytRx Corporation

CytRx to Participate in the H.C. Wainwright BioConnect Virtual Conference

4 years ago - By: CytRx Corporation

CytRx Announces the Appointment of Dr. Stephen Snowdy as Chief Executive Officer

4 years ago - By: CytRx Corporation

CytRx Highlights ImmunityBio's Use of Aldoxorubicin in Ongoing Clinical Studies for Various Forms of Cancer

4 years ago - By: CytRx Corporation

CytRx Provides a Bold Vision on Centurion BioPharma's Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada

4 years ago - By: CytRx Corporation

CytRx Comments on Quarterly Results and Recent Strategic Initiatives

4 years ago - By: CytRx Corporation

CytRx Announces Centurion BioPharma Has Been Invited to Present Plans for a State-of-the-Art Cancer Center in Las Vegas, Nevada

4 years ago - By: CytRx Corporation

CytRx Highlights Orphazyme's Update on Productive Meeting with FDA Regarding Arimoclomol in Niemann-Pick Disease Type C

4 years ago - By: CytRx Corporation

CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment

4 years ago - By: CytRx Corporation

CytRx to Present at Upcoming Virtual LD Micro Conference

4 years ago - By: CytRx Corporation

CytRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

4 years ago - By: CytRx Corporation - Mentions: ORPH

CytRx Highlights Orphazyme’s Published Results From Its Phase 2/3 Trial of Arimoclomol in Niemann-Pick Disease Type C

4 years ago - By: CytRx Corporation

CytRx Comments on Quarterly Results and Recent Strategic Initiatives

4 years ago - By: CytRx Corporation

CytRx Announces Director Election Results from 2021 Annual Meeting of Stockholders

4 years ago - By: CytRx Corporation

CytRx Highlights Preliminary Results of Cohort C of QUILT 88, a Phase 2 Pancreatic Cancer Trial That Includes Aldoxorubicin, Expected to be Released in Q1 2022

4 years ago - By: Benzinga - Mentions: NLST FNMA LWLG GBTC ...

These OTC Securities Had the Most Trading Activity in June

4 years ago - By: CytRx Corporation

CytRx Corporation Announces Closing of $10 Million Offering to Healthcare-Focused Institutional Investor

4 years ago - By: CytRx Corporation

CytRx Corporation Enters Into Securities Purchase Agreement for $10 Million With Healthcare-Focused Institutional Investor

4 years ago - By: CytRx Corporation

CytRx Comments on Orphazyme’s Promising 24-Month Interim Trial Results of Arimoclomol for Niemann-Pick Disease Type C

4 years ago - By: CytRx Corporation

CytRx Notes Orphazyme’s Regulatory Update from the FDA on Arimoclomol for Niemann-Pick Disease Type C

4 years ago - By: PennyStocks.com - Mentions: AMC GTBP ORPH WKHS

3 Penny Stocks To Watch As AMC Stock Makes Headlines In June 2021

4 years ago - By: CytRx Corporation

CytRx to Present at Upcoming Investor Conferences